Company Overview of Karolinska Institutet
Karolinska Institutet is a Swedish university, which specializes in medicine. Several companies in the field of medicine and biotechnology have been founded as a result of the university's research programmes. As a result, Karolinska Institutet cooperates closely with the private sector and has created an investment arm (Karolinska Investment Fund) in order to enhance its scientists' innovations. Founded in 1810, the company is headquartered in Stockholm.
Founded in 1810
46 8 728 64 00
46 8 31 11 01
Key Executives for Karolinska Institutet
Professor of Environmental Toxicology
Professor of Pharmacology
Professor of Neurobiology
Compensation as of Fiscal Year 2016.
Karolinska Institutet Key Developments
NeuroVive Pharmaceutical AB Signs Collaboration Agreement with Karolinska Institutet
Jan 10 17
NeuroVive Pharmaceutical AB announced that a collaboration agreement has been signed with Karolinska Institutet, regarding development of the company's compound NV556 for the treatment of mitochondrial myopathy. Under the collaboration agreement, the team led by Prof. Håkan Westerblad at Karolinska Institutet will study NeuroVive's cyclophilin inhibitor compound NV556 and its effects in experimental models of mitochondrial myopathy. This collaboration expands NeuroVive's presence in the genetic mitochondrial disease field, which is a NeuroVive key focus area and where NeuroVive also develops its NVP015 compounds in mitochondrial respiratory chain diseases. The NV556 compound that is studied under this collaboration is targeting cyclophilin D, and has therefore a different and complementary mode of action than the NVP015 compounds which target the respiratory chain supporting cell energy production.
Karolinska Institutet Presents at BIO-Europe Spring 2016, Apr-04-2016 through Apr-06-2016
Mar 24 16
Karolinska Institutet Presents at BIO-Europe Spring 2016, Apr-04-2016 through Apr-06-2016. Venue: Kistamässan Convention Center, Stockholm, Sweden. Presentation Date & Speakers: Apr-04-2016, Per Svenningsson, Professor, Department of Clinical Neuroscience. Apr-05-2016, Alexander von Gabain, Deputy Vice-Chancellor, Innovation and Commercial Outreach.
Scancell Holdings plc Announces Strategic Collaboration with Karolinska Institutet
Mar 11 16
Scancell Holdings plc announced that it has embarked on a strategic research collaboration with scientists at the Rheumatology Unit at Karolinska Institutet, led by Professors Lars Klareskog and Vivianne Malmström. The collaboration will further explore the scientific and clinical role of citrullinated proteins in the treatment of cancer. Scancell's Moditope® platform technology overcomes the immune suppression induced by tumours themselves, allowing activated T cells to seek out and kill tumour cells that would otherwise be hidden from the immune system. This is achieved by stimulating the production of CD4+ T cells using citrullinated tumour-associated peptide epitopes, which overcome self-tolerance and destroy tumour cells. The teams of Professors Klareskog and Malmström have uncovered a central role for citrullinated proteins in the pathogenesis of the autoimmune disease rheumatoid arthritis. Conversely, Scancell has discovered that citrullinated proteins are also targets on cancer cells and this underpins the use of citrullinated peptides in the Company's Moditope® cancer immunotherapy platform. The groups of Professors Klareskog and Malmström perform research in the area of rheumatology and their work has been published in a number of leading academic journals, including Nature, Lancet, Arthritis & Rheumatism, Nature Medicine, Nature Genetics and Annual Review of Immunology.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|